Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

573 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J. Schlieben S, et al. Among authors: schrappe m. Leukemia. 1996 Jun;10(6):957-63. Leukemia. 1996. PMID: 8667652 Clinical Trial.
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. van Dongen JJ, et al. Among authors: schrappe m. Lancet. 1998 Nov 28;352(9142):1731-8. doi: 10.1016/S0140-6736(98)04058-6. Lancet. 1998. PMID: 9848348
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H. zur Stadt U, et al. Among authors: schrappe m. Klin Padiatr. 2000 Jul-Aug;212(4):169-73. doi: 10.1055/s-2000-9672. Klin Padiatr. 2000. PMID: 10994545 Clinical Trial. German.
Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grümayer ER. Biondi A, et al. Among authors: schrappe m. Leukemia. 2000 Nov;14(11):1939-43. doi: 10.1038/sj.leu.2401922. Leukemia. 2000. PMID: 11069029
Comparative genomic hybridization in childhood acute lymphoblastic leukemia: correlation with interphase cytogenetics and loss of heterozygosity analysis.
Scholz I, Popp S, Granzow M, Schoell B, Holtgreve-Grez H, Takeuchi S, Schrappe M, Harbott J, Teigler-Schlegel A, Zimmermann M, Fischer C, Koeffler HP, Bartram CR, Jauch A. Scholz I, et al. Among authors: schrappe m. Cancer Genet Cytogenet. 2001 Jan 15;124(2):89-97. doi: 10.1016/s0165-4608(00)00330-7. Cancer Genet Cytogenet. 2001. PMID: 11172898
573 results